Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer
Current Oncology · 20.10.2025 · 32 (10) · 583
DOI: 10.3390/curroncol32100583 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 20.10.2025. Verfasst von Paloma Galera und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario de La Princesa, Diego de León 62, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Leukocytes, Mononuclear. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally. The advent of immune checkpoint inhibitors (ICIs) has significantly improved outcomes for a subset of patients; however, predictive biomarkers to identify responders are still lacking. Peripheral blood mononuclear cells (PBMCs) offer a minimally invasive means to assess systemic immune status and have emerged as a potential source of predictive biomarkers. Recent studies have highlighted the role of chemokines and their receptors in modulating immune responses against tumors. In particular, the expression levels of chemokine receptors such as CXCR4 on PBMCs have been associated with patient responses to ICIs. The differences in expression of these receptors correlates with enhanced T cell trafficking and infiltration into the tumor microenvironment, leading to improved antitumor activity. This review consolidates current evidence on the prognostic and predictive value of chemokine receptor expression in PBMCs, like T cells, for NSCLC patients treated with ICIs. Understanding these associations can aid in the development of non-invasive biomarkers to guide treatment decisions and improve patient stratification in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Universitario de La Princesa, Diego de León 62, 28006 Madrid, Spain.
- Instituto de Investigación Sanitaria La Princesa, Diego de León 62, 28006 Madrid, Spain.
- Department of Medicine and Chair of Personalized Precision Medicine, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
ORCID-Profile: Ramon Colomer, Jacobo Rogado
Zitieren
APA
Galera, P., Iglesias-Beiroa, A., Hernández-Marín, B., Bañón, D., Arangoa, T., Castillo, L., Álvarez-Maldonado, M., Gil-Olarte, C., Borregón, R., Iribarren, M., Colomer, R., & Rogado, J. (2025). Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Current Oncology, 32(10), 583. https://doi.org/10.3390/curroncol32100583
Vancouver
Galera P, Iglesias-Beiroa A, Hernández-Marín B, Bañón D, Arangoa T, Castillo L, et al. Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Current Oncology. 2025;32(10):583. doi:10.3390/curroncol32100583
BibTeX
@article{Galera2025,
author = {Galera, Paloma and Iglesias-Beiroa, Antía and Hernández-Marín, Berta and Bañón, Dulce and Arangoa, Teresa and Castillo, Lucía and Álvarez-Maldonado, María and Gil-Olarte, Cristina and Borregón, Rafael and Iribarren, María and Colomer, Ramon and Rogado, Jacobo},
title = {Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {10},
pages = {583},
doi = {10.3390/curroncol32100583}
}
EUVIMED